Table 1 Clinical, biological and pathological characteristics of the oral cavity (OSCC) patients sets: 61 patients from cohort #1, 90 patients of cohort #2 and 151 patients of the merged cohort, in relation with overall survival (OS).

From: Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients

Ā 

Cohort #1 OSCC (nā€‰=ā€‰61)

Cohort #2 (nā€‰=ā€‰90)

Merged cohort (nā€‰=ā€‰151)

Patients (%)

Death (%)

HRa

95% CIb

OSc

Patients (%)

Death (%)

HRa

95% CIb

OSc

Patients (%)

Death (%)

HRa

95% CIb

OSc

Total

61 (100)

31 (50.8)

Ā Ā Ā 

90 (100)

46 (51.1)

Ā Ā Ā 

151 (100)

77 (51)

Ā Ā Ā 

Age

<ā€‰56

24 (39.3)

11 (45.8)

1

Ā 

0.73 (NS)

21 (23.3)

8 (38.1)

1

Ā 

0.25 (NS)

45 (29.8)

19 (42.2)

1

Ā 

0.20 (NS)

ā‰„ā€‰56

37 (60.7)

20 (54.1)

1.14

0.55ā€“2.34

Ā 

69 (76.7)

38 (55.1)

1.55

0.79ā€“3.03

Ā 

106 (70.2)

58 (54.7)

1.40

0.86ā€“2.26

Ā 

Sex

Female

24 (39.3)

10 (41.7)

1

Ā 

0.44 (NS)

34 (37.8)

19 (55.9)

1

Ā 

0.78 (NS)

58 (38.4)

29 (50)

1

Ā 

0.72 (NS)

Male

37 (60.7)

21 (56.8)

1.34

0.65ā€“2.76

Ā 

56 (62.2)

27 (48.2)

0.92

0.51ā€“1.67

Ā 

93 (61.6)

48 (51.6)

1.09

0.69ā€“1.72

Ā 

Alcohold

No

22 (45.8)

8 (36.4)

1

Ā 

0.20 (NS)

57 (70.4)

32 (56.1)

1

Ā 

0.53 (NS)

79 (61.2)

40 (50.6)

1

Ā 

0.99 (NS)

Yes

26 (54.2)

14 (53.8)

1.74

0.75ā€“4.01

Ā 

24 (29.6)

10 (41.7)

0.80

0.41ā€“1.57

Ā 

50 (38.8)

24 (48)

1.00

0.60ā€“1.66

Ā 

Tobaccoe

No

20 (38.5)

6 (30)

1

Ā 

0.077 (NS)

42 (48.8)

22 (52.4)

1

Ā 

0.89 (NS)

62 (44.9)

28 (45.2)

1

Ā 

0.36 (NS)

Yes

32 (61.5)

19 (59.4)

2.23

1.01ā€“4.94

Ā 

44 (51.2)

22 (50)

0.96

0.53ā€“1.73

Ā 

76 (55.1)

41 (53.9)

1.25

0.78ā€“2.01

Ā 

Alcohol and tobaccod

No

25 (52.1)

9 (36.0)

1

Ā 

0.20 (NS)

59 (72.8)

33 (55.9)

1

Ā 

0.48 (NS)

84 (65.1)

42 (50.0)

1

Ā 

0.95 (NS)

Yes

23 (47.9)

13 (56.5)

1.72

0.74ā€“3.97

Ā 

22 (27.2)

9 (40.9)

0.77

0.39ā€“1.53

Ā 

45 (34.9)

22 (48.9)

0.98

0.59ā€“1.65

Ā 

pT

1

14 (23.0)

6 (42.9)

1

Ā 

0.11 (NS)

7 (7.8)

1 (14.3)

1

Ā 

0.11 (NS)

21 (13.9)

7 (33.3)

1

Ā 

0.015*

2

14 (23.0)

7 (50.0)

1.70

0.56ā€“5.14

0.33 (NS)

24 (26.7)

10 (41.7)

3.23

0.82ā€“12.8

0.24 (NS)

38 (25.2)

17 (44.7)

1.93

0.86ā€“4.31

0.13 (NS)

3

21 (34.4)

13 (61.9)

2.43

0.99ā€“5.99

0.057 (NS)

37 (41.1)

22 (59.5)

5.36

1.91ā€“15.0

0.065 (NS)

58 (38.4)

35 (60.3)

3.20

1.72ā€“5.94

0.0024**

4

12 (19.7)

5 (41.7)

1.14

0.35ā€“3.78

0.82 (NS)

22 (24.4)

13 (59.1)

5.44

1.73ā€“17.2

0.064 (NS)

34 (22.5)

18 (52.9)

2.24

1.02ā€“4.92

0.057 (NS)

pN

0

34 (55.7)

17 (50.0)

1

Ā 

0.38 (NS)

47 (52.2)

19 (40.4)

1

Ā 

0.0065**

81 (53.6)

36 (44.4)

1

Ā 

0.0040**

1

5 (8.2)

2 (40.0)

0.88

0.22ā€“3.57

0.87 (NS)

10 (11.1)

6 (60.0)

2.42

0.71ā€“8.24

0.045*

15 (9.9)

8 (53.3)

1.66

0.66ā€“4.13

0.19 (NS)

2

10 (16.4)

6 (60.0)

1.77

0.59ā€“5.28

0.22 (NS)

13 (14.4)

8 (61.5)

2.05

0.75ā€“5.58

0.081 (NS)

23 (15.2)

14 (60.9)

1.98

0.94ā€“4.18

0.026*

3

12 (19.7)

6 (50.0)

2.10

0.66ā€“6.74

0.098 (NS)

20 (22.2)

13 (65.0)

3.03

1.24ā€“7.42

0.0010**

32 (21.2)

19 (59.4)

2.62

1.29ā€“5.30

0.0003**

Differentiationf

Verrucous

0 (0)

0 (0)

Ā Ā 

0.82 (NS)

4 (4.5)

1 (25.0)

0.33

0.10ā€“1.11

0.25 (NS)

4 (2.8)

1 (25.0)

0.37

0.11ā€“1.26

0.30 (NS)

Grade I

43 (76.8)

23 (53.5)

1

Ā Ā 

63 (70.8)

30 (47.6)

1

Ā 

0.041*

106 (73.1)

53 (50.0)

1

Ā 

0.27 (NS)

Grade II

8 (14.3)

4 (50.0)

1.35

0.41ā€“4.40

0.58 (NS)

19 (21.3)

11 (57.9)

1.59

0.73ā€“3.48

0.18 (NS)

27 (18.6)

15 (55.6)

1.54

0.80ā€“2.97

0.13 (NS)

Grade III

5 (8.9)

2 (40.0)

0.81

0.22ā€“3.05

0.78 (NS)

3 (3.4)

3 (100)

Ā 

0.44ā€“26.2

0.031*

8 (5.5)

5 (62.5)

1.35

0.48ā€“3.82

0.41 (NS)

Grade IV

0 (0)

0 (0)

Ā Ā Ā 

0 (0)

0 (0)

3.39

Ā Ā 

0 (0)

0 (0)

Ā Ā Ā 

Marginsg

Negative

44 (78.6)

22 (50.0)

1

Ā 

0.33 (NS)

78 (86.7)

39 (50.0)

1

Ā 

0.17 (NS)

122 (83.6)

61 (50.0)

1

Ā 

0.16 (NS)

Positive

12 (21.4)

7 (58.3)

1.51

0.58ā€“3.95

Ā 

12 (13.3)

7 (58.3)

1.73

0.64ā€“4.67

Ā 

24 (16.4)

14 (58.3)

1.51

0.77ā€“2.94

Ā 

HPV

Negative

60 (98.4)

31 (51.7)

ND

Ā 

0.34 (NS)

87 (96.7)

44 (50.6)

1

Ā 

0.89 (NS)

147 (97.4)

75 (51)

1

Ā 

0.56 (NS)

Positive

1 (1.6)

0 (0)

Ā Ā Ā 

3 (3.3)

2 (66.7)

0.91

0.23ā€“3.58

Ā 

4 (2.6)

2 (50)

0.66

0.21ā€“2.12

Ā 

UICC stage

Stage I

15 (24.6)

5 (33.3)

1

Ā 

0.20 (NS)

5 (5.6)

0 (0)

Ā Ā 

0.024*

20 (13.2)

5 (25)

1

Ā 

0.0036**

Stage II

19 (31.1)

11 (57.9)

2.79

1.04ā€“7.48

0.043*

18 (20)

6 (33.3)

1

Ā 

0.16 (NS)

37 (24.5)

17 (45.9)

2.72

1.17ā€“6.30

0.038*

Stage III

9 (14.8)

4 (44.4)

1.80

0.44ā€“7.40

0.37 (NS)

21 (23.3)

12 (57.1)

1.87

0.74ā€“4.72

0.060 (NS)

30 (19.9)

16 (53.3)

3.56

1.51ā€“8.38

0.0071**

Stage IV

18 (29.5)

11 (61.1)

2.70

1.01ā€“7.23

0.049*

46 (51.1)

28 (60.9)

2.44

1.20ā€“4.95

0.030*

64 (42.4)

39 (60.9)

4.32

2.33ā€“8.01

0.0005***

TP53 mutational status

Wild-type

27 (44.3)

8 (29.6)

1

Ā 

0.0093**

62 (68.9)

35 (56.5)

1

Ā 

0.23 (NS)

55 (36.4)

19 (34.5)

1

Ā 

0.0033**

Mutated

34 (55.7)

23 (67.6)

2.76

1.37ā€“5.59

Ā 

28 (31.1)

11 (39.3)

1.51

0.81ā€“2.80

Ā 

96 (63.6)

58 (60.4)

2.13

1.35ā€“3.35

Ā 

PIK3CA mutational status

Wild-type

54 (88.5)

27 (50)

1

Ā 

0.49 (NS)

79 (87.8)

38 (48.1)

1

Ā 

0.31 (NS)

133 (88.1)

65 (48.9)

1

Ā 

0.17 (NS)

Mutated

7 (11.5)

4 (57.1)

1.44

0.43ā€“4.81

Ā 

11 (12.2)

8 (72.7)

1.48

0.62ā€“3.54

Ā 

18 (11.9)

12 (66.7)

1.53

0.74ā€“3.13

Ā 

Relapse

No

36 (59.0)

16 (44.4)

1

Ā 

0.37 (NS)

57 (63.3)

17 (29.8)

1

Ā 

<ā€‰0.0001**

93 (61.6)

33 (35.5)

1

Ā 

ā€‰<ā€‰0.0001**

Yes

25 (41.0)

15 (60.0)

1.37

0.67ā€“2.81

Ā 

33 (36.7)

29 (87.9)

5.16

2.64ā€“10.1

Ā 

58 (38.4)

44 (75.9)

2.75

1.71ā€“4.43

Ā 

Locoregional relapse

17 (68.0)

9 (52.9)

1

Ā 

0.23 (NS)

21 (63.6)

18 (85.7)

1

Ā 

0.083 (NS)

38 (65.5)

27 (71.1)

1

Ā 

0.017*

Distant metastasis

6 (24.0)

4 (66.7)

1.40

0.39ā€“4.98

0.56 (NS)

5 (15.2)

5 (100)

1.72

0.53ā€“5.62

0.27 (NS)

11 (19.0)

9 (81.8)

1.40

0.61ā€“3.21

0.37 (NS)

Both

2 (8.0)

2 (100)

3.40

0.29ā€“40.0

0.088 (NS)

7 (21.2)

6 (85.7)

2.70

0.75ā€“9.72

0.025*

9 (15.5)

8 (88.9)

3.0

0.94ā€“9.60

0.0033**

  1. Significant (pā€‰<ā€‰0.05) variables are highlighted in bold.
  2. OS: overall survival; NS: not significant; HPV: human papilloma virus; UICC: Union for International Cancer Control; ND: Undefined.
  3. *pā€‰<ā€‰0.05.
  4. **pā€‰<ā€‰0.01.
  5. ***pā€‰<ā€‰0.001.
  6. aHazard ratio (logrank).
  7. b95% Confidence interval.
  8. cLog-rank test.
  9. dInformation available for 48, 81 and 129 patients of cohort #1, cohort #2 and merged cohort respectively.
  10. eInformation available for 52, 86 and 138 patients of cohort #1, cohort #2 and merged cohort respectively.
  11. fInformation available for 56, 89 and 145 patients of cohort #1, cohort #2 and merged cohort respectively.
  12. gInformation available for 56, 90 and 146 patients of cohort #1, cohort #2 and merged cohort respectively.
Back to article page